The Cuban ambassador to Mongolia, Jorge Ferrer, met with Mr. Jargalsaikhan Gungaa, President of the United Mongolian Association of Diabetic Patients. Mr. Munkhsukh Jargalsaikhan, Manager of that organization, also participated.
They discussed the Cuban drug HEBERPROT-P, the only one of its kind in the world for the treatment of diabetic foot ulcers in advanced stages and with a high risk of amputation. They also discussed the challenges of its use in this country.
The Diabetic Association expressed interest in the continued presence and use of the drug in this country for the benefit of Mongolian patients.
This drug, registered and used in Mongolia and 25 other countries, was developed by the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba. It has favored the quality of life of almost 450 thousand people in the world. It reduces the amputation rate to less than five percent despite having stage 4 or 5 ulcers on the Wagner scale.
Studies carried out concluded that, despite the cost of its application, it constitutes a significant benefit. It avoids the application of costly surgical techniques, amputations and disability. Public expenditures on social assistance for disabilities are also avoided or reduced.
This medicine was recognized with the Gold medal of the World Intellectual Property Organization (WIPO) in 2011.
Both parties agreed to continue exchanging and cooperating to address the challenges for the continued presence and use of the drug in this country.